NCT05990426Recruiting
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
The Impact of Alternate Day Fasting After Surgery for Patients Undergoing chemoTherapy (FAST Study)
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously shown to be safe. There is no data specifically addressing the impact of a fasting diet regimen on side effects of chemotherapy during treatment for ovarian and endometrial cancers in the front-line setting. The information gathered from this study will inform future trials about the role of time-restricted eating and its impact on side-effects associated with chemotherapy as well as its role in improvement of quality of life for women afflicted with these debilitating diseases.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 Apr 2023
- Start date
- 16 Oct 2023
- Primary completion date
- Aug 2027
- Lead sponsor
- Northwestern University
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT05990426
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 16 Oct 2023 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are not planning to undergo chemotherapy at Northwestern Medicine
- Patients who have undergone prior systemic therapy to treat a malignancy in the last 2 years.
Other illness
- Patients who have been diagnosed with medication-dependent diabetes, recent myocardial infarction, stroke, pulmonary embolus, renal failure, or any condition that may preclude ability to tolerate a short-term fast will be excluded.
- Patients who take medications where conditions may be influenced in the presence of fasting (e.g. hypertension, electrolyte abnormalities, migraines) will be monitored by their treating physician for any necessary adjustments in these medications.
Lab values
- BMI of 50+ or those with a diagnosed eating disorder. Patients who take medications for blood glucose regulation (e.g. insulin), and/or require treatment with therapeutic doses of anticoagulants will be excluded.
- Patients whose oncologist has not provided clearance for their participation
Other
- Patients engaged in shift work (i.e., those who work nights, 3rd shift)
- Unable or unwilling to follow a diet regimen or participate in ketone measurements
- ECOG status greater than 1
Who the study is looking for
- Female; ≥ 18 years of age
- Confirmed or high suspicion for endometrial, ovarian, fallopian tube or primary peritoneal cancer, and are able and expecting to undergo adjuvant chemotherapy following hysterectomy for treatment of disease, as determined by their treating physician
- Fluent in spoken and written English
- Own a smart phone
- Have access to the internet to complete surveys
- ECOG status of 0 or 1
- Willingness to sign informed consent form
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Northwestern Memorial Hospital Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.